A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors PharmAbcine
- 11 Sep 2019 According to a PharmAbcine media release, compqany plans to complete this trial within this year.
- 17 Jan 2019 Status changed from not yet recruiting to recruiting.
- 02 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 3 Jan 2019.